[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Stojanović M, Goldner B, Djukić S: [Unusual biological behaviour of femoral liposarcoma]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):468-71
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual biological behaviour of femoral liposarcoma].
  • INTRODUCTION: Liposarcoma of a bone is a very rare tumour of the fatty marrow, originating from lipoblasts.
  • Its frequency is 1:1000 of all bone tumours.
  • Surgical resection-amputation, chemotherapy and radiotherapy are the therapeutic methods of choice.
  • There was a histologically proved liposarcoma of a high grade of malignancy.
  • According to the therapeutic protocol, chemotherapy and radiotherapy were applied.
  • During the period of 12 years, the patient had a relapse on the stump, metastatic dissemination in the soft tissue of small pelvis twice, once in the left scapular region and in the inguinal lymph nodes, six operations and 8-year accumulation of metastatic deposits in the lung.
  • CONCLUSION: Unusual behaviour of the liposarcoma of high grade malignancy with which the patient has been living for 12 years, could be explained by the patient's strong immunobiological system in the struggle to retain its vitality and mobility.
  • [MeSH-major] Femoral Neoplasms / pathology. Liposarcoma / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Soft Tissue Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929542.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


2. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. De Padua M, Bhandari TP, Pingle J: Primary osteoliposarcoma of the bone. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteoliposarcoma of the bone.
  • Osteoliposarcoma are rare tumors of the bone.
  • Radiologically, a tumor in the lower end of the right femur was seen extending into the soft tissue.
  • The patient received three cycles of neo-adjuvant chemotherapy followed by limb-salvage surgery with provisions for a custom-made prosthesis.
  • A histopathological study of the excision specimen revealed areas of pleomorphic liposarcoma with numerous osteoblasts associated with areas of osteoid surrounded by neoplastic cells.
  • The final diagnosis was osteoliposarcoma.
  • Only 21% tumor necrosis (effects of chemotherapy) was observed.
  • Presently, 26 months following diagnosis, the patient is fine with no evidence of local recurrence or distant metastasis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Liposarcoma / diagnosis. Liposarcoma / pathology. Osteosarcoma / diagnosis. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Femur / pathology. Femur / radiography. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136790.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Turcotte RE, Ferrone M, Isler MH, Wong C: Outcomes in patients with popliteal sarcomas. Can J Surg; 2009 Feb;52(1):51-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue sarcoma involving the popliteal fossa remains challenging because it is difficult to achieve wide margins with limb salvage in this location.
  • Adjuvant therapy is frequently necessary, and limb function can be adversely affected.
  • Frequent histologic diagnoses were liposarcoma (n = 6), synovial sarcoma (n = 4) and leiomyosarcoma (n = 3).
  • Treatment consisted of limb salvage in 15 patients and amputation in 3.
  • Fourteen patients had radiotherapy, 4 had chemotherapy, and 3 needed partial sciatic nerve resection.
  • [MeSH-major] Knee. Outcome Assessment (Health Care). Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / statistics & numerical data. Chemotherapy, Adjuvant. Databases, Factual. Female. Humans. Limb Salvage. Lung Neoplasms / secondary. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Sciatic Nerve / surgery. Surgical Wound Dehiscence / etiology. Surgical Wound Infection / etiology. Thrombophlebitis / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):512-7 [17174515.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):160-6 [11372947.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] Ann Surg. 1968 Jul;168(1):47-53 [4299767.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1005-22 [7226034.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1632-9 [3948134.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1987 Oct;58(5):516-22 [3425281.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9 [1938558.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):19-31 [8472413.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1398-405 [8620414.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):90-100 [9973980.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:225-33 [16957647.001]
  • [Cites] Surg Oncol. 1999 Dec;8(4):211-4 [11128835.001]
  • (PMID = 19234652.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637647
  •  go-up   go-down


5. Goss G, Demetri G: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol; 2000 Aug;9(2):53-9
Genetic Alliance. consumer health - Retroperitoneal liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
  • For patients with recurrent and unresectable liposarcoma, treating the sarcoma while maintaining quality of life becomes the major therapeutic goal.
  • Importantly, patients with advanced recurrent disease demonstrate the need for multidisciplinary team involvement, with timely consideration of palliative surgical, radiation therapy, and chemotherapy options.
  • In addition to the development of new cytotoxic agents, patients may be candidates for novel strategies such as differentiation therapies or anti-angiogenic approaches.
  • The recent explosion of knowledge regarding the cytogenetics, molecular, and cellular biology of liposarcomas allows us to remain positive that new translational therapies will be developed to improve the clinical outcomes of patients with these diseases.
  • [MeSH-major] Chromans / administration & dosage. Liposarcoma / drug therapy. Liposarcoma / surgery. Neoplasm Recurrence, Local / drug therapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / surgery. Thiazoles / administration & dosage. Thiazolidinediones
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094323.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Chromans; 0 / Thiazoles; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  • [Number-of-references] 26
  •  go-up   go-down


6. Buyukhatipoglu H, Sevinc A, Camci C, Buyukberber S, Sari I: A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation. Clin Lab Haematol; 2006 Oct;28(5):343-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation.
  • Dedifferentiated and well-differentiated liposarcomas are the two pathological subtypes of liposarcoma, based on the WHO classification.
  • Transition from well-differentiated to dedifferentiated liposarcoma is a well-recognized phenomenon.
  • This process largely is believed to progress in a time-dependant manner; however, time is not the only factor of importance.
  • To date, the coexistence of AML and liposarcoma has not been reported in the literature.
  • In this paper, we report on a case of coexistence of AML and liposarcoma, and on the unusual behavior of a well-differentiated tumor after dedifferentiation occurs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Liposarcoma / chemically induced
  • [MeSH-minor] Abdominal Neoplasms / pathology. Adult. Bone Neoplasms / secondary. Female. Humans

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999727.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G: Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology; 2007;73(1-2):58-64
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients.
  • Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients or not is controversial.
  • METHODS: We present a large institutional experience of sarcoma patients treated with this therapy option.
  • Thirty-eight patients with bone (n = 17) and soft tissue sarcomas (n = 21) were included.
  • RESULTS: Following chemotherapy and/or surgery, but prior to high-dose chemotherapy, diagnoses were made of: no evidence of disease (NED; n = 12), partial remission (n = 17), stable disease (n = 3) and progressive disease (PD; n = 6).
  • CONCLUSION: A subgroup of patients with NED before high-dose chemotherapy gained survival benefit.
  • Therefore, we emphasize the value of high-dose chemotherapy as a treatment option for younger patients with a good performance status in partial or complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chondrosarcoma / drug therapy. Chondrosarcoma / surgery. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / surgery. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] : (c) 2008 S. Karger AG, Basel
  • (PMID = 18334832.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Fleshman R, Mayerson J, Wakely PE Jr: Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer; 2007 Dec 25;111(6):491-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They also searched their tissue database for all HGS cases that had prior FNA biopsy findings.
  • RESULTS: A total of 107 FNA samples from 98 patients (age range, 13-90 years, with a male:female ratio of 1:1) had an FNA diagnosis of HGS, or had HGS and a prior FNA diagnosis of another entity.
  • The positive predictive value of an FNA diagnosis of HGS was 97% (88 of 91 cases).
  • Fifty-four cases were diagnosed as HGS, not otherwise specified, 8 as myxofibrosarcoma, 8 as osteosarcoma, 5 as malignant peripheral nerve sheath tumor, 5 as leiomyosarcoma, 4 as Ewing sarcoma, 4 as liposarcoma, 2 as epithelioid sarcoma, and 1 as angiosarcoma.
  • FNA diagnosis was confirmed histologically in 88% of cases, clinically in 7% of cases, and cytogenetically in 1% of cases; 3% of cases had false-positive results and 1 patient was lost to follow-up.
  • Sixteen of 19 patients received neoadjuvant chemotherapy based on the FNA diagnosis alone.
  • CONCLUSIONS: A cytopathologic diagnosis of HGS was found to be accurate in 88 of 97 cases (91%) with follow-up.
  • A FNA biopsy diagnosis of HGS appears to be clinically reliable in a high percentage of cases when used in close conjunction with the orthopedic team.
  • [MeSH-major] Biopsy, Fine-Needle. Cytodiagnosis. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941014.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Chughtai A, Cronin P, Lucas DR, Prager R, Kazerooni EA: Metastatic shoulder liposarcoma to the right ventricle: CT findings. J Thorac Imaging; 2007 May;22(2):195-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic shoulder liposarcoma to the right ventricle: CT findings.
  • Metastatic cardiac liposarcoma is rare.
  • A right ventricular liposarcoma metastasis is described in a 46-year-old man, who was admitted with significant shortness of breath and fatigue, and in whom a large lobulated low attenuation mass occupying most of the right ventricular cavity, with extension through the right ventricular apex and a small-to-moderate pericardial effusion was detected by electrocardiogram-gated cardiac computed tomography.
  • The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier.
  • The histopathologic analysis revealed a liposarcoma, similar to the one resected in the left arm 3 years earlier.
  • Electrocardiogram-gated cardiac computed tomography was able to visualize the metastatic tumor within the heart, accurately evaluate cardiac function and allow for prompt surgical treatment that produced relief of symptoms, and assess for further metastatic disease within the thorax.
  • [MeSH-major] Bone Neoplasms / pathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Liposarcoma / diagnosis. Shoulder / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527130.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


10. Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP: Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. Hum Pathol; 2009 Jul;40(7):1040-4
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy.
  • Myxoid liposarcoma exhibits a peculiar clinical behavior, with a tendency to spread to serosal membranes, distant soft tissues, and bones, even in the absence of lung metastases.
  • Therapy-related hematological neoplasms are well-known side effects of cytotoxic chemotherapy.
  • We describe an exceptional case of metastatic myxoid liposarcoma of the spine associated with therapy-related refractory anemia with excess of blasts in a 37-year-old woman who underwent multi-agent chemotherapy for a myxoid liposarcoma of the left thigh.
  • Microscopic examination of the bone marrow biopsy revealed dysplastic features, with abnormal localization of immature precursors and micromegakaryocytes, and islands of undifferentiated oval small/medium-size cells, suggestive of acute myeloid leukemia arising in the setting of a myelodysplastic syndrome.
  • Cytogenetic analyses of bone marrow aspirate disclosed the presence of 2 different rearrangements, subsequently confirmed by fluorescent in situ hybridization and was crucial in making the correct diagnosis.
  • [MeSH-major] Liposarcoma, Myxoid / pathology. Myelodysplastic Syndromes / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Anemia, Refractory / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / pathology. Chromosomes, Human, Pair 11. Combined Modality Therapy / adverse effects. Female. Humans. Leukemia, Myeloid, Acute / pathology. Soft Tissue Neoplasms / pathology. Thigh / pathology


11. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Benjamin RS, Pollock RE: Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Mar 1;70(3):760-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy.
  • PURPOSE: To evaluate the local control rates and patterns of metastatic relapse in patients with localized myxoid liposarcoma treated with conservation surgery and radiotherapy (RT).
  • PATIENTS AND METHODS: Between 1960 and 2003, 127 patients with non-metastatic myxoid liposarcoma were treated with conservation surgery and RT at our institution.
  • Of the 127 patients, 46% underwent preoperative RT (median dose, 50 Gy) and 54% underwent postoperative RT (median dose, 60 Gy).
  • Also, 28% received doxorubicin-based chemotherapy as a part of their treatment.
  • Of the 27 patients who developed distant metastases, 48% did so in the retroperitoneum, 22% in other extrapulmonary soft tissues, 22% in the lung, 15% in bone, and 4% in the liver.
  • CONCLUSION: The results of our study have shown that RT and conservation surgery for localized myxoid liposarcoma provide excellent local control.
  • Distant metastatic relapse tended to occur in the retroperitoneum and other nonpulmonary soft tissues.
  • Therefore, staging and surveillance imaging should include the abdomen and pelvis, as well as the thorax, for patients with localized myxoid liposarcoma.
  • [MeSH-major] Liposarcoma, Myxoid / radiotherapy. Liposarcoma, Myxoid / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy / methods. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retroperitoneal Neoplasms / secondary. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892916.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer; 2010 Jan;46(1):72-83
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
  • BACKGROUND: Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients' characteristics.
  • As ifosfamide is frequently applied in first line systemic therapy, we aimed to establish prognostic and predictive factors for outcome to ifosfamide-based therapy.
  • METHODS: A retrospective, exploratory analysis was performed on data from 1337 advanced STS patients who received first-line ifosfamide-containing chemotherapy.
  • Predictive factor analysis showed that compared to doxorubicin monotherapy, patients who benefited less from ifosfamide-based therapies were leiomyosarcoma patients in terms of OS, and patients with liposarcoma for response.
  • CONCLUSION: In this study, we established an independent set of prognostic and predictive factors for outcome to ifosfamide-based chemotherapy in advanced STS patients.
  • This study provides important information for the interpretation and design of clinical trials for specific STS entities and may contribute to further treatment individualisation of advanced STS patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Ifosfamide / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome


13. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol; 2010 Dec;21(12):2436-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.
  • BACKGROUND: The predictive value of grade for benefit from adjuvant chemotherapy (AC) in soft tissue sarcoma (STS) patients has never been explored.
  • Grade was assessed according to the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system after central review.
  • Young age, non-well-differentiated liposarcoma histology, deep location, bone and/or neurovascular invasion and grade 2 or 3 were significantly associated with a higher likelihood to receive AC.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439343.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


14. Chugh R, Thomas D, Wathen K, Thall PF, Benjamin RS, Maki RS, Samuels BL, Keohan ML, Priebat DA, Baker LH: Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):9001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.
  • Rules for early termination within each disease type were based on a hierarchical Bayesian probability model accounting for correlation of the responses of the 10 disease types.
  • Tissue specimens were analyzed by immunohistochemistry for c-kit, PDGFRα, PDGFR****223'3f NEEDS TO BE ADDED TO TIMES NEW ROMAN GREEK FONT****, AKT, PTEN, FKHR, and by allelic PCR analysis for PDGFRα exon 18.
  • Patients received prior chemotherapy and all had progressive disease.
  • Four month progression-free survival (PFS) rates follow: all sarcoma subtypes 18% (27/147), angiosarcoma 10% (1/10), Ewing sarcoma 0% (0/13), fibrosarcoma 29% (2/7), liposarcoma 32% (9/28), leiomyosarcoma (LMS) 20% (6/30), malignant fibrous histiocytoma 1/15 (7%), osteosarcoma 18% (3/17), peripheral nerve sheath tumor 20% (1/5), rhabdomyosarcoma 0% (0/2), synovial sarcoma 20% (4/20).
  • CONCLUSIONS: Further investigation of imatinib in the therapy of liposarcoma, LMS, and fibrosarcoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol; 2009 Sep 1;27(25):4188-96
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
  • PURPOSE: To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide.
  • Time to progression (TTP) was the primary efficacy end point, based on confirmed independent review of images.
  • CONCLUSION: Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy.
  • Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / administration & dosage. Drug Resistance, Neoplasm. Ifosfamide / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Tetrahydroisoquinolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia. Disease-Free Survival. Drug Administration Schedule. Europe. Female. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. North America. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Failure. Young Adult


16. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant; 2004 Jul;34(1):37-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.
  • The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established.
  • In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1).
  • Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT.
  • Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation / methods. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome


17. Mrad K, Sassi S, Smida M, Oubiche F, Mekni A, Romdhane KB: Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica; 2004 Dec;96(6):475-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone.
  • BACKGROUND: Primary malignant mesenchymoma of the bone is a rare neoplasm consisting of two or more unrelated malignant mesenchymal components.
  • The literature reports fewer than 20 cases, most of which were composed of osteosarcoma and liposarcoma.
  • OBSERVATION: We report an exceedingly rare case of primary malignant mesenchymoma of bone composed of rhabdomyosarcoma, osteosarcoma, and a minor chondrosarcoma component, arising in the right proximal humerus of a 15-year-old girl.
  • The rhabdomyosarcomatous component was present in the initial biopsy and persisted in surgical specimen following chemotherapy.
  • CONCLUSION: Effect of chemotherapy is enigmatic since rhabdomyosarcomatous component could appear, persist or disappear after chemotherapy according to literature.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / therapeutic use. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Chondrosarcoma / radiography. Chondrosarcoma / surgery. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Methotrexate / therapeutic use. Neoplasm Proteins / analysis. Osteolysis / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant mesenchymoma .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792374.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Desmin; 0 / Neoplasm Proteins; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 12
  •  go-up   go-down


18. Röper B, Licht T: [Soft tissue sarcoma of the extremities: current state of the art of adjuvant therapy]. MMW Fortschr Med; 2006 Apr 27;148(17):32-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma of the extremities: current state of the art of adjuvant therapy].
  • [Transliterated title] Mit der Strahlentherapie wird die Amputation zur Ausnahme.
  • Treatment by an experienced multidisciplinary team offers the best chance of achieving permanent tumor control.
  • Patients with large G3 tumors can be given adjuvant chemotherapy to reduce the risk of distant metastases.
  • [MeSH-major] Bone Neoplasms / therapy. Extremities. Sarcoma / therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Humans. Intraoperative Care. Liposarcoma / diagnosis. Magnetic Resonance Imaging. Middle Aged. Particle Accelerators. Postoperative Care. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711485.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  • [Number-of-references] 0
  •  go-up   go-down


19. Chuman H: [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2003 May;30(5):626-33
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma].
  • MFH-like histological changes are observed in many bone and cartilage sarcomas, and some renal cell carcinomas and malignant lymphomas.
  • These changes occur in many subtypes of sarcomas such as osteogenic sarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, and liposarcoma.
  • Patients with MFH often have repeated recurrences before a diagnosis is made, and the tumor is partially resected.
  • The sensitivity of MFH to radiotherapy and chemotherapy is insufficient, and evidence is lacking for adjuvant treatment.
  • Rescue following initial treatment failure is extremely difficult.
  • Local control of 70% to 90% can be achieved if a correct diagnosis is made, and a curative wide resection or salvage wide resection are done early.
  • For treatment of bone and soft tissue sarcoma, a correct diagnosis and initial treatment are extremely important.
  • Many cases need to be accumulated in joint clinical studies across fields according to organ and specialty, and effective treatment method developed.
  • We need to advance the standardization of treatment for MFH, and eliminate wrong initial treatment through the active provision of information.
  • [MeSH-major] Bone Neoplasms. Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Prognosis. Radiotherapy, Adjuvant. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / therapy. Survival Rate

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B, French Federation of Cancer Centers Sarcoma Group: Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer; 2001 Jul 15;92(2):359-68
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, despite progress, surgery alone is rarely curative, and analysis of the causes of failures and of other prognostic factors are warranted to ascertain treatment orientations.
  • Median tumor size was 15 cm (range, 2--70 cm); 31% of tumors presented with neurovascular or bone involvement.
  • Liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma represented 66% of the tumors.
  • Multimodality treatment included surgery (150 patients), radiotherapy (92 patients), and chemotherapy (77 patients).
  • The main prognostic factors for survival were initial metastases and surgery, which represented the major treatment-linked factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466691.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Sugawara Y, Murase K, Kikuchi K, Sakayama K, Miyazaki T, Kajihara M, Miki H, Mochizuki T: Measurement of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging and deconvolution analysis: a preliminary study in musculoskeletal tumors. J Comput Assist Tomogr; 2006 Nov-Dec;30(6):983-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 14 patients with musculoskeletal tumors, TBF showed wide variances: the lowest of 9.6 mL.100 mL.min in liposarcoma and the highest of 182.0 mL.100 mL.min in osteosarcoma.
  • After chemotherapy, the TBF values (7.9, 11.0, and 11.7 mL.
  • [MeSH-major] Bone Neoplasms / blood supply. Bone Neoplasms / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / blood supply. Muscle Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082707.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


23. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Göbel U, Kremens B, Fölsch UR, Aulitzky WE, Voûte PA, Zoubek A, Jürgens H: Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol; 2001 Nov;12(11):1619-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
  • BACKGROUND: Ewing tumor treatment involves high cumulative doses of alkylating agents and topoisomerase inhibitors, drugs capable of inducing second cancers.
  • PATIENTS AND METHODS: Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine. doxorubicin, ifosfamide and/or cyclophosphamide, and antinomycin D, with or without etoposide as a randomized question.
  • RESULTS: After a median observation time of 56 months (32 months for survivors), 6 of 690 patients had developed second cancers: MDS/AML, two, ALL/NHL, two, squamous cell carcinoma, one, liposarcoma, one.
  • The cumulative second cancer risk five years after diagnosis of the Ewing tumor was 0.0093 for the total group, zero for patients without etoposide, and 0.0118 with etoposide.
  • Additional phase II high-dose therapy increased the risk to 0.0398 after five years.
  • High-dose therapy, and less markedly, etoposide, may contribute to the overall second cancer risk.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822764.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement